Company intelligence / Profile preview

EligoChem

Sandwich, Kent, United Kingdom

Ownership: Private
Development stage: Other

Overview

EligoChem is a drug discovery platform company focused on designing and developing safer drugs, leveraging its proprietary amphiphilic compound technology. This platform enables the creation of compounds with reduced toxicity and improved absorption by optimizing three-dimensional chemical properties. The company is currently developing helical antimicrobial peptides in collaboration with the AMR Centre, targeting Gram-negative bacterial infections with low resistance potential, a program supported by CARB-X funding.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculePeptides
Industry: Biotech

Partnerships

AMR CentreCARB-X

Beyond the preview

Go deeper on EligoChem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EligoChem.

Explore the full profile